Payment overview · 2025
General Payments
$153.36
6 reported records · 4 companies
Healthcare provider profile · identity verified
Jeffery W. Coco, MD
Allopathic & Osteopathic Physicians|Internal Medicine · NEW ORLEANS, LA · NPI 1831127513
Verified facts
What the public records show
CMS Open Payments records show Jeffery W. Coco, MD received $153.36 in general payments during 2025 across 6 reported records.
Merck Sharp & Dohme LLC accounted for 34.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Cabenuva, Pifeltro.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ISENTRESS as an associated drug or biological on 37 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Isentress by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PIFELTRO as an associated drug or biological on 7921 records involving 2912 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Pifeltro by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CABENUVA as an associated drug or biological on 13941 records involving 3305 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Cabenuva by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported DOVATO as an associated drug or biological on 18732 records involving 3540 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Dovato by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $52.97 | 34.5% | 2 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $50.78 | 33.1% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $25.31 | 16.5% | 1 | 2025 |
| Theratechnologies Inc. | Unresolved — no canonical attribution shown | $24.30 | 15.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $153.36 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| PIFELTRO Normalized: pifeltro |
Drug | Merck Sharp & Dohme LLC | $52.97 | 2 | 2025 |
Source payment records
|
|||||
| DELSTRIGO Normalized: delstrigo |
Drug | Merck Sharp & Dohme LLC | $32.00 | 1 | 2025 |
Source payment records
|
|||||
| CABENUVA Normalized: cabenuva |
Drug | ViiV Healthcare Company | $31.10 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $25.31 | 1 | 2025 |
Source payment records
|
|||||
| EGRIFTA Normalized: egrifta |
Drug | Theratechnologies Inc. | $24.30 | 1 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $19.68 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CABENUVA cabenuva |
2025 | Cabenuva | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PIFELTRO pifeltro |
2025 | Pifeltro | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | ISENTRESS open payments reported associated product |
CMS Open Payments — General Payments 37 supporting records · 24 recipient NPIs · example record 1238003286 |
Isentress · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | PIFELTRO open payments reported associated product |
CMS Open Payments — General Payments 7921 supporting records · 2912 recipient NPIs · example record 1237992198 |
Pifeltro · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | CABENUVA open payments reported associated product |
CMS Open Payments — General Payments 13941 supporting records · 3305 recipient NPIs · example record 1189508908 |
Cabenuva · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | DOVATO open payments reported associated product |
CMS Open Payments — General Payments 18732 supporting records · 3540 recipient NPIs · example record 1189508902 |
Dovato · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 319 | 40 |
| Tivicay | Dolutegravir Sodium | 317 | 29 |
| Amlodipine Besylate | Amlodipine Besylate | 282 | 36 |
| Descovy | Emtricitabine/Tenofov Alafenam | 255 | 25 |
| Gabapentin | Gabapentin | 222 | 30 |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 191 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 170 | 24 |
| Prezcobix | Darunavir/Cobicistat | 170 | 16 |
| Lisinopril | Lisinopril | 147 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 146 | 19 |
| Metformin Hcl | Metformin Hcl | 140 | 16 |
| Tramadol Hcl | Tramadol Hcl | 139 | 16 |
| Losartan Potassium | Losartan Potassium | 136 | 17 |
| Omeprazole | Omeprazole | 124 | 16 |
| Ibuprofen | Ibuprofen | 123 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 103 | 13 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 93 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 89 | 13 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 77 | 11 |
| Genvoya | Elviteg/Cob/Emtri/Tenof Alafen | 77 | suppressed |
| Odefsey | Emtricitab/Rilpiviri/Tenof Ala | 76 | suppressed |
| Furosemide | Furosemide | 66 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 65 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 65 | suppressed |
| Acyclovir | Acyclovir | 64 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 61 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 61 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 60 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 58 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 58 | suppressed |
| Juluca | Dolutegravir/Rilpivirine | 57 | suppressed |
| Triumeq | Abacavir/Dolutegravir/Lamivudi | 57 | suppressed |
| Darunavir | Darunavir | 53 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 53 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 52 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 52 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 52 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 50 | suppressed |
| Meloxicam | Meloxicam | 49 | suppressed |
| Naproxen | Naproxen | 49 | suppressed |
| Baclofen | Baclofen | 48 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 48 | suppressed |
| Potassium Chloride | Potassium Chloride | 48 | suppressed |
| Ritonavir | Ritonavir | 48 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 44 | suppressed |
| Ketoconazole | Ketoconazole | 43 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 42 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 41 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 40 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 39 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 37 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 37 | suppressed |
| Emtricitabine-Tenofovir Disop | Emtricitabine/Tenofovir (Tdf) | 36 | suppressed |
| Januvia | Sitagliptin Phosphate | 34 | suppressed |
| Pregabalin | Pregabalin | 34 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 34 | suppressed |
| Loperamide | Loperamide Hcl | 32 | suppressed |
| Ondansetron Odt | Ondansetron | 32 | suppressed |
| Carvedilol | Carvedilol | 30 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 30 | suppressed |
| Atazanavir Sulfate | Atazanavir Sulfate | 29 | suppressed |
| Finasteride | Finasteride | 29 | suppressed |
| Mupirocin | Mupirocin | 29 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 29 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 28 | suppressed |
| Bupropion Xl | Bupropion Hcl | 27 | suppressed |
| Glipizide Er | Glipizide | 27 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 27 | suppressed |
| Allopurinol | Allopurinol | 26 | suppressed |
| Prednisone | Prednisone | 26 | suppressed |
| Vascepa | Icosapent Ethyl | 26 | suppressed |
| Edurant | Rilpivirine Hcl | 25 | suppressed |
| Famotidine | Famotidine | 25 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 25 | suppressed |
| Temazepam | Temazepam | 25 | suppressed |
| Abacavir | Abacavir Sulfate | 24 | suppressed |
| Clonazepam | Clonazepam | 24 | suppressed |
| Fluconazole | Fluconazole | 24 | suppressed |
| Alprazolam | Alprazolam | 23 | suppressed |
| Emtricitabine | Emtricitabine | 23 | suppressed |
| Evotaz | Atazanavir Sulfate/Cobicistat | 23 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 23 | suppressed |
| Trulicity | Dulaglutide | 23 | suppressed |
| Eliquis | Apixaban | 22 | suppressed |
| Efavirenz-Emtric-Tenofov Disop | Efavirenz/Emtricit/Tenofovr Df | 21 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 21 | suppressed |
| Mirtazapine | Mirtazapine | 21 | suppressed |
| Lamivudine | Lamivudine | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Testosterone | Testosterone | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Latanoprost | Latanoprost | 19 | suppressed |
| Diazepam | Diazepam | 18 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 17 | suppressed |
| Symtuza | Darunavir/Cob/Emtri/Tenof Alaf | 17 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 16 | suppressed |
| Dovato | Dolutegravir Sodium/Lamivudine | 15 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Azithromycin | Azithromycin | 13 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 13 | suppressed |
| Entecavir | Entecavir | 13 | suppressed |
| Ezetimibe | Ezetimibe | 13 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Ozempic | Semaglutide | 13 | suppressed |
| Pifeltro | Doravirine | 13 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 12 | suppressed |
| Cabenuva | Cabotegravir/Rilpivirine | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Methadone Hcl | Methadone Hcl | 12 | suppressed |
| Nevirapine Er | Nevirapine | 12 | suppressed |
| Niacin Er | Niacin | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | 11 |
| Diclofenac Potassium | Diclofenac Potassium | 11 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Isentress | Raltegravir Potassium | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Phenytoin | Phenytoin | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
| Timolol Maleate | Timolol Maleate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $153.36 · 6 records | Merck Sharp & Dohme LLC | APRETUDE, CABENUVA, DELSTRIGO, EGRIFTA, PIFELTRO, The Cologuard Plus Collection Kit | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Cabenuva play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Merck Sharp & Dohme LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error